In this episode, we analyse CSL Limited (ASX: CSL), a $134 billion market cap biotechnology company specialising in plasma-derived therapies, vaccines, and rare disease treatments. Operating in over 100 countries with 25,000 employees, CSL is a global leader in life-saving medical innovations through its core businesses, including CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor.
We explore its strong economic moat, financial health, and growth performance, including a 226% increase in dividends over the past decade. Despite recent share price dips, analysts view it as potentially undervalued by 20%.
Tune in as we discuss CSL’s long-term prospects, past returns (up 249% over 10 years), future earnings growth potential, and insights into its recent acquisitions and latest announcements.
Please Note: This is not a buy, nor sell, recommendation. This is general information only.
00:00 Introduction to Investor Motivation Podcast
00:11 Discussing CSL: An Australian Business Success Story
00:27 CSL’s History: A Legacy Since 1916
00:39 The Business Deep Dive: Episode 6
17:28 North American Market: CSL's Global Reach
17:49 Rachel’s Opinion: Hold on CSL?
18:04 Robert’s Investment Strategy: Dollar-Cost Averaging in CSL
18:41 Current Market Conditions & Stock Market Growth
19:02 CSL in the Context of an Aging Population
19:13 Where to Find More Information: Rachel and Robert’s Platforms
19:59 Conclusion & See You Next Time
Robert Goudie, CFP, GradDipFP (ASIC Reg 235974) and Rachael Todman, GradDipFP (ASIC Reg 1270413), are authorised representatives of Consortium Private Wealth Pty Ltd | ABN 74 616 250 965 AFS Licence 495401.
----------------------------------------------------------------
More Freebies you should check out*
Ebooks, Online Courses, Video Blogs, Podcasts | Free resources covering a range of financial fundamentals to build your knowledge*
https://www.consortiumpw.com.au/elearning/
*Follow us on our social media *
Website: https://www.consortiumpw.com.au/
Instagram: https://www.instagram.com/consortiumprivatewealth/
Facebook Page: https://www.facebook.com/consortiumpw
To contact us directly please email info@consortiumpw.com.au or call 03 5382 3460. We're here to help!
Advice Disclaimer || Any advice given by the presenter/s has been prepared without considering your individual objectives, financial situation or needs. So, before you act on the advice you should think about whether the advice suits your objectives, financial situation or needs. If the advice relates to acquiring a financial product you should obtain a copy of the Product Disclosure Statement for that product and consider it before making a decision. This presentation has been prepared by Consortium Private Wealth Pty Ltd (ABN 74 616 250 965) (AFSL 495401). If you require advice which takes into account your objectives, financial situation and needs you should speak to a financial adviser.
Robert Goudie (ASIC Reg 235974), Ashley Rowan (ASIC Reg 433899), Olivia Glare (ASIC Reg 1262290), Rachael Todman (ASIC Reg 1270413) & Amy Lehmann (ASIC Reg 1292710) are Authorised Representatives of Consortium Private Wealth Pty Ltd ABN 74 616 250 965 AFS Licence 495401.
12